Avenzo Therapeutics

SAN DIEGO, CA · Founded 2022 · CIK 0001947742 · Biotech · Private

Oncology therapeutics using novel drug development approaches

avenzotx.com →
Grants
—
No SBIR or STTR on record
Sector median: 1
Raised
$79M
2 Form D · Sep 2025
13 months since last filing
Contracts
—
No federal contracts on record
Patents
—
No published records under this name
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Private capital raisedForm D · SEC$31,499,999
Private capital raisedForm D · SEC$47,230,787
Form D · SEC

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2213Milestone Pharmaceuticals Inc.—$91M
2214BE COOL PHARMACEUTICS, LLC——
2215Xeris Pharmaceuticals, Inc.—$80M
2216Avenzo Therapeutics—$79M
2217Oragenics, Inc.—$67M
2218Discidium Biosciences, LLC——
2219KINETIQ THERAPEUTICS LLC——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Founders & Team

From Form D filings · 12 related persons
  • Athena CountouriotisDirector · Executive Officer
  • Jakob Dupont, M.D., M.A.Director
  • Simeon GeorgeDirector
  • Carl GordonDirector
  • Mohammad HirmandExecutive Officer
  • Judith LiDirector
  • Scott LipmanExecutive Officer
  • Patrick MachadoDirector
  • Garry NicholsonDirector
  • Michael RomeDirector
  • Brian SunExecutive Officer
  • Paolo TombesiExecutive Officer

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.